Inside Precision Medicine October 18, 2024
Phenomix Sciences, a biotech focusing on obesity phenotyping and biomarker testing, will partner with genetic testing and counseling provider InformedDNA to provide targeted obesity treatment based on underlying biology.
Obesity is a very heterogeneous condition that can manifest for many different reasons. The approval of Novo Nordisk’s GLP-1 agonist Wegovy (semaglutide) for weight loss in 2021 and Eli Lilly’s combined GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist Zepbound (tirzepatide) in 2022 has added new and effective options to the market for those affected.
But these drugs do not work for everyone, and more effective use of biomarkers and health data can match the right drug to the right person quickly and avoid the wasted time and costs of using a...
Today's Sponsors
Today's Sponsor